Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°èÇмú´ëȸ : 2022-03-19±³À°ÀÏÀÚ : 2022-03-19
±³À°Àå¼Ò : ¼Ûµµ ÄÁº¥½Ã¾Æ ȸÀǵ¿2Ãþ ÇÁ¸®¹Ì¾î º¼·ë
±³À°ÁÖÁ¦ :
Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç¥ÀûÄ¡·á¿¬±¸È¸
´ã´çÀÚ : ±èÀÎÁ¤
¿¬¶ôó : 02-741-8540
À̸ÞÀÏ :
kalc@lungca.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
ÀÎõ±¤¿ª½Ã±³À°½Ã°£ : 3 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í »çÀüµî·Ï ȸ¿ø: 50,000¿ø/ ºñȸ¿ø 60,000¿ø ÇöÀåµî·Ï ȸ¿ø: 60,000¿ø/ ºñȸ¿ø 70,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-19 ¼Ûµµ ÄÁº¥½Ã¾Æ ȸÀǵ¿2Ãþ ÇÁ¸®¹Ì¾î º¼·ë 13:00~13:20 Diagnostic tools for small variant driver mutations Â÷À±Áø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03-19 ¼Ûµµ ÄÁº¥½Ã¾Æ ȸÀǵ¿2Ãþ ÇÁ¸®¹Ì¾î º¼·ë 13:20~13:40 Current of lung cancer with EGFR driver mutation Á¶ÁØÇö(ÃæºÏÀÇ´ë)
±³À°½Ã°£ 03-19 ¼Ûµµ ÄÁº¥½Ã¾Æ ȸÀǵ¿2Ãþ ÇÁ¸®¹Ì¾î º¼·ë 13:40~14:00 Current of lung cancer with other driver mutations (KRAS, BRAF, HER2, MET skipping, etc) ±èÀξÖ(°Ç±¹ÀÇ´ë)
Åä·Ð 03-19 ¼Ûµµ ÄÁº¥½Ã¾Æ ȸÀǵ¿2Ãþ ÇÁ¸®¹Ì¾î º¼·ë 14:00~14:10 Q & A ()
ÈÞ½Ä 03-19 ¼Ûµµ ÄÁº¥½Ã¾Æ ȸÀǵ¿2Ãþ ÇÁ¸®¹Ì¾î º¼·ë 14:10~14:30 Coffee break ()
±³À°½Ã°£ 03-19 ¼Ûµµ ÄÁº¥½Ã¾Æ ȸÀǵ¿2Ãþ ÇÁ¸®¹Ì¾î º¼·ë 14:30~14:50 Diagnostic tools for driver structural variation ¼º¿¬Àº(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-19 ¼Ûµµ ÄÁº¥½Ã¾Æ ȸÀǵ¿2Ãþ ÇÁ¸®¹Ì¾î º¼·ë 14:50~15:10 Management of ALK/ROS1 fusion NSCLC ÃÖÀ缺(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 03-19 ¼Ûµµ ÄÁº¥½Ã¾Æ ȸÀǵ¿2Ãþ ÇÁ¸®¹Ì¾î º¼·ë 15:10~15:30 Management of RET, NKTR, and other fusion (+) NSCLC ÃÖ¼±ÇÏ(°æºÏÀÇ´ë)
Åä·Ð 03-19 ¼Ûµµ ÄÁº¥½Ã¾Æ ȸÀǵ¿2Ãþ ÇÁ¸®¹Ì¾î º¼·ë 15:30~15:40 Q & A ()
ÈÞ½Ä 03-19 ¼Ûµµ ÄÁº¥½Ã¾Æ ȸÀǵ¿2Ãþ ÇÁ¸®¹Ì¾î º¼·ë 15:40~16:00 Coffee break ()
±³À°½Ã°£ 03-19 ¼Ûµµ ÄÁº¥½Ã¾Æ ȸÀǵ¿2Ãþ ÇÁ¸®¹Ì¾î º¼·ë 16:00~16:20 SMARCA4 deficient lung cancer ÀÓÁØÇõ(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 03-19 ¼Ûµµ ÄÁº¥½Ã¾Æ ȸÀǵ¿2Ãþ ÇÁ¸®¹Ì¾î º¼·ë 16:20~16:40 NSCLC without identifiable driver mutations ¹ÚÁö¿µ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 03-19 ¼Ûµµ ÄÁº¥½Ã¾Æ ȸÀǵ¿2Ãþ ÇÁ¸®¹Ì¾î º¼·ë 16:40~17:00 Small cell lung cancer Á¤Àç¿Ï(¿ø±¤ÀÇ´ë)